QUEST (12+ years), VOYAGE (6-11 years)
DUPIXENT improved quality of life in asthma patients.1,9
Up to 71% of asthma patients aged 12+ years experienced an improved quality of life, as measured by AQLQ(S),e-g with DUPIXENT 200 mg Q2W + SOC vs 55% with placebo + SOC (OR: 2.02 [95% CI: 1.24, 3.32]) (baseline blood EOS ≥300 cells/µL, QUEST).1
65% of patients experienced an improved quality of life with DUPIXENT 300 mg Q2W + SOC vs 55% with placebo + SOC (OR: 1.79 [95% CI: 1.13, 2.85]) (baseline blood EOS ≥300 cells/μL, QUEST).1
eResponder rates at Week 52 in QUEST were assessed as secondary endpoints and defined as an improvement in score of 0.5 or more (scale ranged from 1 to 7 for AQLQ[S]).1
fAQLQ(S) was assessed as a secondary endpoint but was ordered after the point at which the hierarchical break occurred. Results are descriptive.9
gAQLQ(S): Asthma Quality of Life Questionnaire, Standardized Version, a patient-reported measure of asthma-related quality of life. Higher scores indicate better quality of life; a global score is calculated ranging from 1 to 7. The minimum clinically important difference is 0.5.1
Up to 73% of children with asthma experienced an improved quality of life, as measured by PAQLQ(S)-IA.9,h,i
PAQLQ(S)-IA was studied in children aged ≥7 to <12 years. Results are descriptive.
hAnalysis of change at Week 24 was not multiplicity controlled; result is descriptive. Definitive conclusions cannot be made.9
iPAQLQ(S)-IA: Pediatric Asthma Quality of Life Questionnaire With Standardized Activities-Interviewer Administered: Children aged ≥7 to <12 years at randomization responded to questions about health-related quality of life on a 7-point scale (7=no impairment; 1=severe impairment) at Weeks 12, 24, 36, and 52. The ability of DUPIXENT to impact health-related quality of life was assessed by evaluating the LSM change in PAQLQ(S)-IA scores.9